Cargando…

Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database

PURPOSE: Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Giner-Soriano, Maria, Vedia Urgell, Cristina, Roso-Llorach, Albert, Morros, Rosa, Capellà, Dolors, Castells, Xavier, Ferreira-González, Ignacio, Troncoso Mariño, Amelia, Diògene, Eduard, Elorza, Josep Mª, Casajuana, Marc, Bolíbar, Bonaventura, Violan, Concepció
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735136/
https://www.ncbi.nlm.nih.gov/pubmed/26823179
http://dx.doi.org/10.1136/bmjopen-2015-010144
_version_ 1782413025462976512
author Giner-Soriano, Maria
Vedia Urgell, Cristina
Roso-Llorach, Albert
Morros, Rosa
Capellà, Dolors
Castells, Xavier
Ferreira-González, Ignacio
Troncoso Mariño, Amelia
Diògene, Eduard
Elorza, Josep Mª
Casajuana, Marc
Bolíbar, Bonaventura
Violan, Concepció
author_facet Giner-Soriano, Maria
Vedia Urgell, Cristina
Roso-Llorach, Albert
Morros, Rosa
Capellà, Dolors
Castells, Xavier
Ferreira-González, Ignacio
Troncoso Mariño, Amelia
Diògene, Eduard
Elorza, Josep Mª
Casajuana, Marc
Bolíbar, Bonaventura
Violan, Concepció
author_sort Giner-Soriano, Maria
collection PubMed
description PURPOSE: Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Safety and Costs in Atrial Fibrillation (ESC-FA) study is to analyse the drugs used for the management of the disease in real-use conditions, particularly the antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of phase I of the ESC-FA study and the baseline characteristics of newly diagnosed patients with atrial fibrillation in Catalonia, Spain. PARTICIPANTS: The data source is System for the Improvement of Research in Primary Care (SIDIAP) database. The population included are all patients with non-valvular atrial fibrillation diagnosis registered in the electronic health records during 2007–2012. FINDINGS TO DATE: A total of 22 585 patients with non-valvular atrial fibrillation were included in the baseline description. Their mean age was 72.8 years and 51.6% were men. The most commonly prescribed antithrombotics were vitamin K antagonists (40.1% of patients) and platelet aggregation inhibitors (32.9%); 25.3% had not been prescribed antithrombotic treatment. Age, gender, comorbidities and co-medication at baseline were similar to those reported for previous studies. FUTURE PLANS: The next phase in the ESC-FA study will involve assessing the effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes’ rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation.
format Online
Article
Text
id pubmed-4735136
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47351362016-02-09 Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database Giner-Soriano, Maria Vedia Urgell, Cristina Roso-Llorach, Albert Morros, Rosa Capellà, Dolors Castells, Xavier Ferreira-González, Ignacio Troncoso Mariño, Amelia Diògene, Eduard Elorza, Josep Mª Casajuana, Marc Bolíbar, Bonaventura Violan, Concepció BMJ Open Pharmacology and Therapeutics PURPOSE: Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Safety and Costs in Atrial Fibrillation (ESC-FA) study is to analyse the drugs used for the management of the disease in real-use conditions, particularly the antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of phase I of the ESC-FA study and the baseline characteristics of newly diagnosed patients with atrial fibrillation in Catalonia, Spain. PARTICIPANTS: The data source is System for the Improvement of Research in Primary Care (SIDIAP) database. The population included are all patients with non-valvular atrial fibrillation diagnosis registered in the electronic health records during 2007–2012. FINDINGS TO DATE: A total of 22 585 patients with non-valvular atrial fibrillation were included in the baseline description. Their mean age was 72.8 years and 51.6% were men. The most commonly prescribed antithrombotics were vitamin K antagonists (40.1% of patients) and platelet aggregation inhibitors (32.9%); 25.3% had not been prescribed antithrombotic treatment. Age, gender, comorbidities and co-medication at baseline were similar to those reported for previous studies. FUTURE PLANS: The next phase in the ESC-FA study will involve assessing the effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes’ rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation. BMJ Publishing Group 2016-01-28 /pmc/articles/PMC4735136/ /pubmed/26823179 http://dx.doi.org/10.1136/bmjopen-2015-010144 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Pharmacology and Therapeutics
Giner-Soriano, Maria
Vedia Urgell, Cristina
Roso-Llorach, Albert
Morros, Rosa
Capellà, Dolors
Castells, Xavier
Ferreira-González, Ignacio
Troncoso Mariño, Amelia
Diògene, Eduard
Elorza, Josep Mª
Casajuana, Marc
Bolíbar, Bonaventura
Violan, Concepció
Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title_full Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title_fullStr Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title_full_unstemmed Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title_short Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
title_sort effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase i esc-fa protocol study and baseline characteristics of a cohort from a primary care electronic database
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735136/
https://www.ncbi.nlm.nih.gov/pubmed/26823179
http://dx.doi.org/10.1136/bmjopen-2015-010144
work_keys_str_mv AT ginersorianomaria effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT vediaurgellcristina effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT rosollorachalbert effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT morrosrosa effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT capelladolors effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT castellsxavier effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT ferreiragonzalezignacio effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT troncosomarinoamelia effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT diogeneeduard effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT elorzajosepma effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT casajuanamarc effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT bolibarbonaventura effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase
AT violanconcepcio effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphaseiescfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase